Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer

Cancer Gene Therapy

Volumn 20, Issue 5, 2013, Pages 298-307

  Miceli, C ^a   Tejada, A ^a   Castaneda, A ^a   Mistry, S J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adriamycin; Breast cancer; Combination therapy; Stathmin; Taxol

Indexed keywords

ANTISTATHMIN RIBOZYME; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; RIBOZYME; STATHMIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CLONOGENESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, NUDE; RNA, CATALYTIC; STATHMIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 84878011763     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.21     Document Type: Article

References (38)

1. Mistry S, Atweh GF. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002; 69: 299-304. (Pubitemid 35244131)
2. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. Embo J 1996; 15: 5290-5298. (Pubitemid 26336212)
3. Mistry S, Luo X, Atweh GF. Transcriptional regulation of phosphoprotein p18 during monocytic differentiation of U937 leukemic cells. Cell Mol Biol Res 1995; 41: 103-110.
4. Cooper H, McDuffie E, Braverman R. Human peripheral lymphocyte growth regulation and response to phorbol esters is linked to synthesis and phosphorylation of the cytosolic protein, prosolin. J Immunol 1989; 143: 956-963. (Pubitemid 19203825)
5. Schubart UK, Xu J, Fan W, Cheng G, Goldstein H, Alpini G et al. Widespread differentiation stage-specific expression of the gene encoding phosphoprotein p19 (metablastin) in mammalian cells. Differentiation 1992; 51: 21-32.
6. Luo X, Mookerjee B, Ferrari A, Mistry S, Atweh GF. Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 1994; 269: 10312-10318.
7. Marklund U, Osterman O, Melander H, Bergh A, Gullberg M. The phenotype of a 'Cdc2 kinase target site-deficient' mutant of oncoprotein 18 reveals a role of this protein in cell cycle control. J Biol Chem 1994; 269: 30626-30635.
8. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996; 84: 623-631. (Pubitemid 26071742)
9. Horwitz S, Shen HJ, He L, Dittmar P, Neef R, Chen J et al. The microtubuledestabilizing activity of metablastin (p19) is controlled by phosphorylation. J Biol Chem 1997; 272: 8129-8132. (Pubitemid 27147759)
10. Mistry S, Li HC, Atweh GF. Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin. Biochem J 1998; 334: 23-29. (Pubitemid 28420966)
11. Mistry S, Atweh GF. Stathmin inhibition enhances okadaic acid-induced mitotic arrest: a potential role for stathmin in mitotic exit. J Biol Chem 2001; 276: 31209-31215. (Pubitemid 37384989)
12. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000; 83: 311-318. (Pubitemid 30453569)
13. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW et al. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 2000; 18: 722-730.
14. Roos G, Brattsand G, Landberg G, Marklund U, Gullberg M. Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia 1993; 7: 1538-1546. (Pubitemid 23319129)
15. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R et al. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 1998; 78: 701-709. (Pubitemid 28418300)
16. Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A et al. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumors. Br J Cancer 2000; 82: 142-150. (Pubitemid 30008973)
17. Oishi Y, Nagasaki K, Miyata S, Matsura M, Nishimura S, Akiyama F et al. Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 2007; 52: 271-279.
18. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003; 63: 8939-8947. (Pubitemid 38064074)
19. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569. (Pubitemid 47185946)
20. Mistry S, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001; 11: 41-49. (Pubitemid 32199393)
21. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 2005; 4: 1821-1829. (Pubitemid 43056965)
22. Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA et al. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene 1995; 11: 743-750.
23. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchroage independent growth in vitro. Proc Natl Acad Sci USA 1975; 72: 4435-4439.
24. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice correlates with cell growth in semi-solid medium. Cell 1974; 3: 355-359.
25. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-721. (Pubitemid 20054204)
26. Lang JY, Chen H, Zhou J, Zhang YX, Zhang WX, Li MH et al. Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res 2005; 11: 3455-3464. (Pubitemid 40627900)
27. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R et al. p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 2000; 88: 685-691.
28. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999; 18: 5954-5958. (Pubitemid 29520452)
29. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003-1012.
30. Partridge A, Winer A. Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years. Clin Breast Cancer 2000; 1: 164-165.
31. Ibrahim N, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. The Lancet 2000; 355: 281-283. (Pubitemid 30068521)
32. Mills KM, Johnson DM, Middlebrooks M, Burton GV. Possible drug-associated pancreatitis after paclitaxel-cremophor administration. Pharmacotherapy 2000; 20: 95-97. (Pubitemid 30036108)
33. Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci 1999; 112: 3713-3722.
34. Jourdain L, Curmi P, Sobel A, Dominique P, Carlier MF. Stathmin: a tubulinsequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997; 36: 10817-10821. (Pubitemid 27396235)
35. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Biol Chem 1981; 91: 479-487. (Pubitemid 12215635)
36. Meng XL, Su D, Wang L, Gao Y, Hu YJ, Yang HJ et al. Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxelcontaining regimens in locally advanced breast cancer. Genet Test Mol Biomarkers 2012; 16: 689-694.
37. Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 2012; 118: 4660-4669.
38. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 6864-6869. (Pubitemid 35424074)